Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Nootropics Depot Launches SulfoMax, the World's Highest Sulforaphane Supplement

Nootropics Depot is a leading supplement company setting benchmark standards for quality and transparency in the industry. Founded with a mission to empower consumers with knowledge about what they put into their bodies, Nootropics Depot offers a wide range of high-quality cognitive enhancement and general health supplements.

News provided by

Nootropics Depot

Sep 08, 2026, 09:52 ET

Share this article

Share toX

Share this article

Share toX

The new formula converts its sulforaphane in a glass of water rather than the stomach, a design the Arizona supplement R&D company arrived at after months of dissolution testing showed the conversion enzyme does not survive stomach acid.

TEMPE, Ariz., Sept. 8, 2026 /PRNewswire/ -- Nootropics Depot released SulfoMax, a powdered supplement that delivers 27mg of active sulforaphane per serving, a level the company states is the highest available in the category. The delivery method is the real story. SulfoMax finishes its conversion chemistry in a glass of water, five minutes before it is consumed.

SulfoMax delivers 27 mg of active sulforaphane per serving, converted in the glass rather than the capsule.
SulfoMax delivers 27 mg of active sulforaphane per serving, converted in the glass rather than the capsule.
The four steps behind SulfoMax: stir, convert, wait five minutes, drink. The conversion happens in the glass because myrosinase is largely inactivated at stomach-acid pH.
The four steps behind SulfoMax: stir, convert, wait five minutes, drink. The conversion happens in the glass because myrosinase is largely inactivated at stomach-acid pH.

Sulforaphane itself is too unstable to bottle. The standard industry workaround pairs glucoraphanin, its shelf-stable precursor, with myrosinase, the enzyme that converts it, inside a capsule, and leaves the reaction to happen after swallowing. Nootropics Depot's analytical lab put that assumption through a Distek dissolution tester with simulated gastric fluid. At stomach-acid pH, myrosinase is largely inactivated. The same reaction that proceeds normally at intestinal pH barely happens in acid, which means much of the precursor in a conventional capsule passes through without ever becoming sulforaphane.

SulfoMax moves the reaction outside the body, and every component of the powder has a job in that chemistry. Potassium bicarbonate buffers the glass of water into the pH range where myrosinase stays active. Within that window, the enzyme, supplied by 240mg of white mustard seed powder, the richest myrosinase source among the brassicas the company evaluated, hydrolyzes the glucoraphanin from 360mg of black kale extract standardized to 17%. A 12mg dose of vitamin C serves as a cofactor that pushes the conversion further, and an acacia fiber base keeps enzyme and precursor suspended together long enough to finish the job. Five minutes after mixing, the glass holds active sulforaphane. Then it can be diluted with more water and drank, or mixed with other things like InfiniFiber and InfiniGreens.

The design exploits an asymmetry in the chemistry: the enzyme is fragile in acid, but the finished compound is not. Sulforaphane itself is stable in gastric fluid, so once the conversion is complete, digestion no longer threatens it. UPLC testing confirmed that the finished serving's sulforaphane survives simulated gastric fluid at both pH 1.2 and pH 3. Heat sensitivity is also why SulfoMax is a powder rather than a capsule or a pre-converted liquid, since sulforaphane degrades rapidly at elevated temperatures.

The compound's reputation in longevity research rests largely on one pathway. Research suggests sulforaphane modifies cysteine residues on the Keap1 protein, releasing the Nrf2 transcription factor to switch on the body's own cytoprotective enzymes. Rather than acting as a direct antioxidant, sulforaphane supports the expression of the cell's endogenous defense systems, which is why studies describe support for antioxidant redox balance, a healthy inflammatory response, and long-term cellular resilience. The brain is part of that story as well. Cell-model research suggests Nrf2 activation in astrocytes helps condition neighboring neurons against oxidative stress, a form of cross-protection behind sulforaphane's growing profile in work on cognitive resilience, mental clarity, and focus. None of that machinery matters, the company argues, unless active sulforaphane actually arrives, which is the problem SulfoMax was engineered to solve.

"We watched the capsule approach fail in simulated gastric fluid over and over," said Paul Eftang, CEO of Nootropics Depot. "Once you have seen myrosinase quit in stomach acid enough times, the answer is obvious: do the chemistry in a glass of water, where we control the pH, then verify the result on the UPLC. Then you know you are getting the same amount of sulforaphane each time you take a dose." 

The formulation took almost two years of iteration, with each formulation measured at Omnient Lab, the company's sister laboratory in Tempe Arizona, rather than estimated from precursor math. SulfoMax is taken once daily in the morning, best taken with food: stir, wait five minutes, drink.

SulfoMax is available now at nootropicsdepot.com in 30-serving ($59.99) and 60-serving ($99.99) jars, manufactured in a cGMP, FDA-registered facility in Arizona with third-party lab testing and a published certificate of analysis. Read more about the SulfoMax R&D story.

About Nootropics Depot

Nootropics Depot is a leading supplement company setting benchmark standards for quality and transparency in the industry. Founded in 2013, Nootropics Depot's mission has been to educate consumers on the science behind dietary supplements, and to advance the lab testing and quality control standards of the industry. Their stance is that consumers should be able to trust the products they buy, and that the brands selling those products have a duty to ensure they are using modern validated science. Nootropics Depot offers a wide range of high-quality cognitive enhancement and general health supplements. The company's commitment to quality and transparency is evident in their rigorous testing procedures, easily accessible Certificates of Analysis (COAs), and lab testing results available on every product page. In addition, they have formed a Scientific Advisory Board with board certified doctors, PhD researchers, and botanists to ensure that consumers can trust that scientific rigor is being upheld in everything they do. Nootropics Depot's newly redesigned website features a user-friendly interface, and includes an innovative quiz to help beginners find the right supplements for their needs. With partnerships with third-party labs, and collaboration with the Future Nutra Foundation, Nootropics Depot continues to push the boundaries of supplement quality and consumer education. For more information about Nootropics Depot's products and their commitment to transparency, visit nootropicsdepot.com.

Media Contact:
Michael Packman
Nootropics Depot
[email protected]

SOURCE Nootropics Depot

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Nootropics Depot CEO Paul Eftang Calls for New Reishi Bioactive Standardization Paradigm

Nootropics Depot CEO Paul Eftang Calls for New Reishi Bioactive Standardization Paradigm

Nootropics Depot announced the publication of a new white paper by CEO Paul Eftang titled "Beyond the Marker: A Bioactives-First Standard for Reishi...

Nootropics Depot CEO Challenges Conventional Electrolyte Science In New White Paper

Nootropics Depot CEO Challenges Conventional Electrolyte Science In New White Paper

Nootropics Depot announced the publication of a new white paper by CEO Paul Eftang titled "The Electrolyte Delusion: Intelligent Hydration Beyond the ...

More Releases From This Source

Explore

Supplementary Medicine

Supplementary Medicine

Fitness/Wellness

Fitness/Wellness

Health Care & Hospitals

Health Care & Hospitals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content

About

  • About PR Newswire
  • About Cision
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.